UP - logo
E-viri
Recenzirano Odprti dostop
  • Safety and efficacy of addi...
    Mohamed, Ahmed Abdalla; Radwan, Tarek Ahmed; Mohamed, Mohamed Mahmoud; Mohamed, Hatem Abdellatif; Mohamed Elemady, Mohamed Farid; Osman, Safinaz Hassan; Safan, Tamer Fayez; Khair, Tamer Mohamed; Ali, Norhan Abdelaleem; Fahmy, Rania Samir; Belita, Mohamed Ibrahim; Abdalla, Shady Rady; Seleem, Ahmed Abdelaziz; Atta, Ehab Mohi; Zaid, Osama Ismail; Ragab, Ahmed Shaker; Salem, Ahmed Essam; AlKholy, Badawy Mohamed

    BMC anesthesiology, 09/2018, Letnik: 18, Številka: 1
    Journal Article

    Patients undergoing craniotomy operations are prone to various noxious stimuli, many strategies are commenced to provide state of analgesia, for better control of the stress response and to overcome its undesired effects on the haemodynamics and post-operative pain. Scalp nerves block are considered one of these strategies. This study was conceived to evaluate the effect of addition of hyaluronidase to the local anaesthetic mixture used in the scalp nerves block in patients undergoing elective craniotomy operations. 64 patients undergoing elective craniotomy operations were enrolled in this prospective randomized, double-blind comparative study. Patients were randomly assigned to two groups. Group LA, patients subjected to scalp nerves block with 15 ml bupivacaine 0.5%, 15 ml lidocaine 2%, in 1:400000 epinephrine. Group H as Group LA with15 IU /ml Hyaluronidase. Patients in the H group showed lower VAS values for 8 h postoperative, compared to the LA group. The haemodynamic response showed lower values in the H group, compared to the LA group. Those effects were shown in the intraoperative period and for 6 h post-operative. No difference was detected regarding the incidence of complications nor the safety profile. Our data supports the idea that addition of hyaluronidase to the local anesthetic mixture improves the success rates of the scalp nerves block and its efficacy especially during stressful intraoperative periods and in the early postoperative period. No evident undesirable effects in relation to the addition of hyaluronidase. Clinical Trial registry on ClinicalTrials.gov , NCT 03411330 , 25-1-2018.